In the PURE-01 study (NCT02736266), we aimed to evaluate the ability to predict the pathologic complete response (pT0N0) after pembrolizumab by using clinical and tumor biomarkers.
Predicting the pathologic complete response after neoadjuvant pembrolizumab in muscle-invasive bladder cancer
Bandini, Marco;Colecchia, Maurizio;Pederzoli, Filippo;Gandaglia, Giorgio;Salonia, Andrea;Briganti, Alberto;Montorsi, Francesco;Necchi, Andrea
2021-01-01
Abstract
In the PURE-01 study (NCT02736266), we aimed to evaluate the ability to predict the pathologic complete response (pT0N0) after pembrolizumab by using clinical and tumor biomarkers.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
